

1. Funktionelle Abklärung

1.1. Maximale Sauerstoffaufnahme als Parameter für das operative Risiko bei großen Lungenoperationen

Brunelli A, Belardinelli R, Refari M, et al: Peak oxygen consumption during cardiopulmonary exercise test improves risk stratification in candidates to major lung resection. *Chest* 2009; 135(5):1260-1267.

1.2.1. Leitlinien der ERS und der ESTS für die prätherapeutische Risikobeurteilung von Patienten vor einer radikalen Therapie bei Lungenkrebs

Brunelli A, Charloux A, Bolliger CT et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). *Eur Respir J* 2009; 34(1):17-41.

2. Lungenkarzinom

2.1. Staging

2.1.1. Stagingmethoden

2.1.1.1. PET-CT

Fischer B, Lassen U, Mortensen J et al. Preoperative staging of lung cancer with combined PET-CT. *N Engl J Med* 2009; 36(1):32-39.

2.1.1.2. PET beim Rundherd

Clifton IJ, Scarsbrook AF, Muers MF: No lung cancer resection of PET positive lesions: an audit of the lung cancer multidisciplinary team. *Eur Resp J* 2009; 33(4):941-942.

2.1.1.3. Stellenwert der PET-CT und EBUS-TBNA bei potenziell operablen Lungenkrebspatienten

Hwangbo B, Kim SK, Lee HS et al. Application of endobronchial ultrasound-guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable non-small cell lung cancer. *Chest* 2009; 135(5):1280-1287.

2.1.1.4. Komplikationen der EUS-FNA

Aerts JG, Kloover J, Los J et al. EUS-FNA of enlarged necrotic lymph nodes may cause infectuous mediastinitis. *J Thorac Oncol* 2008; 3(10):1191-1193.

2.1.2. Neues TNM-System

Chansky K, Sculier JP, Crowley J et al. The IASLC lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *J Thorac Oncol* 2009; 4(7):792-801.

Goldstraw P, Crowley J, Chansky K et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. *J Thorac Oncol* 2007; 2(8):706-714.

Groome PA, Bolejack V, Crowley J et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. *J Thorac Oncol* 2007; 2(8):694-705.

Postmus PE, Brambilla E, Chansky K et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2007; 2(8):686-693.

Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2007; 2(7):593-602.

Rusch VW, Asamura H, Watanabe H et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2009; 4(5):568-577.

Rusch VW, Crowley J, Giroux DJ et al. The IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2007; 2(7):603-612.

Shepherd FA, Crowley J, Van Houtte P et al. The IASLC lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *J Thorac Oncol* 2007; 2(12):1067-1077.

Vallières E, Shepherd FA, Crowley J et al. The IASLC lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2009; 4(9):1049-1059.

2.2. OP-Indikation

2.2.1. OP-Indikation bei mediastinalem Lymphknotenbefall

Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. *Lancet* 2009; 374:379-386.

Cerfolio RJ, Bryant AS: Survival of patients with unsuspected N2 (stage IIIA) non-small cell lung cancer. *Ann Thorac Surg* 2008; 86:362-367.

Cerfolio RJ, Maniscalco L, Bryant AS et al. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena und who survives. *Ann Thorac Surg* 2008; 86:912-920.

Misthos P, Sepsas E, Kokotsakis J et al. The significance of one-station N2 disease in the prognosis of patients with non-small cell lung cancer. *Ann Thorac Surg* 2008; 86:1626-1631.

2.2.2. Nachresektion bei R1- Befall am Bronchus?

Collaud S, Bongiovanni M, Pache JC et al. Survival according to the site of bronchial microscopic residual disease after lung resection for non-small cell lung cancer. *J Thorac Cardiovasc* 2009; 137(3):622-626.

2.3. OP-Technik

2.3.1. Bedeutung der VATS-Lobektomie bei der Therapie von Lungenkarzinompatienten

Farjah F, Wood DE, Mulligan MS et al. Safety and efficacy of video-assisted versus conventional lung resection for lung cancer. *J Thorac Cardiovasc Surg* 2009; 137(6):1415-1421.

Whitson BA, D’Cunha J, Andrade RS et al. Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity. *Ann Thorac Surg* 2008; 86:1735-1744.

Yan TD, Black D, Bannon PG et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small cell lung cancer. *J Clin Oncol* 2009; 27(15):2553-2562.

2.3.2. Innovation bei bronchoplastischen Operationen

Chida M, Minowa M, Miyoshi S et al. Extended sleeve lobectomy for locally advanced lung cancer. *Ann Thorac Surg* 2009; 87:900-905.

Lucchi M, Melfi F, Ribecchini A et al. Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. *J Thorac Cardiovasc Surg* 2007; 134(2):373-377.

Milman S, Kim AW, Warren WH et al. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. *Ann Thorac Surg* 2009; 88:945-951.

2.4 Erweiterte Resektionen

2.4.1. Langzeitergebnisse bei T4 Tumoren

Yildizeli B, Darteville P, Fadel E et al. Results of primary surgery with T4 non-small cell lung cancer during a 24-year period in a single center: the benefit is worth the risk. *Ann Thorac Surg* 2008; 86:1065-1075.

2.4.2. OP-Ergebnisse bei Infiltration von Wirbelkörpern

Anraku M, Waddell TK, de Perrot M et al. Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. *J Thorac Cardiovasc Surg* 2009; 137(2):441-447.

Bolton WD, Rice DC, Goodyear A et al. Superior sulcus tumors with vertebral body involvement: a multimodality approach. *J Thorac Cardiovasc Surg* 2009; 137(6):1379-1387.

2.5. Limitierte Resektionen und andere lokale Behandlungsoptionen (Radiofrequenzablation, Strahlentherapie)

Baumann P, Nyman J, Hoyer M et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small cell lung cancer patients treated with stereotactic body radiotherapy. *J Clin Oncol* 2009; 27(20):3290-3296.

Kilic A, Schuchert MJ, Pettiford BL et al. Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly. *Ann Thorac Surg* 2009; 87:1662-1668.

Lanuti M, Sharma A, Digumarthy SR et al. Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2009; 137(1):160-166.

Yoshimatsu R, Yamagami T, Terayama K et al. Delayed and recurrent pneumothorax after radiofrequency ablation of lung tumors. *Chest* 2009; 135(4):1002-1009.

2.6. Postoperative Lebensqualität

Balduyck B, Hendriks J, Lauwers P et al. Quality of life after lung cancer surgery: a prospective pilot study comparing bronchial sleeve lobectomy with pneumonectomy. *J Thorac Oncol* 2008; 3(6):604-608.

Balduyck B, Hendriks J, Lauwers P et al. Quality of life evolution after lung cancer surgery: a prospective study in 100 patients. *Lung Cancer* 2007; 56:423-431.

Burfeind WR, Tong BC, O'Branski E et al. Quality of life outcomes are equivalent after lobectomy in the elderly. *J Thorac Cardiovasc Surg* 2008; 136(3):597-604.

Salati M, Brunelli A, Xiumè F et al. Quality of life in the elderly after major lung resection for lung cancer. *Interact Cardiovasc Thorac Surg* 2009; 8:79-83.

Schulte T, Schniewind B, Dohrmann P et al. The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer. *Chest* 2009; 135(2):322-329.

2.7. Facharztspezialität und Langzeitergebnisse bei Lungenkrebsoperationen

Farjah F, Flum DR, Varghese TK et al. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. *Ann Thorac Surg* 2009; 87:995-1006.

3. Postoperative Komplikationen

3.1. Bedeutung der perioperativen Antibiotikaprohylaxe

Schussler O, Dermine H, Alifano M et al. Should we change antibiotic prophylaxis for lung surgery? Postoperative pneumonia is the critical issue. *Ann Thorac Surg* 2008; 86:1727-1734.

4. Mesotheliom

4.1. Bedeutung des Mesothelioms für Prognose und Diagnostik des malignen Pleuramesothelioms

Davies HE, Sadler RS, Bielsa S et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. *Am J Resp Crit Care Med* 2009; 180:437-444.

Schneider J, Hoffmann H, Dienemann H et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3(11):1317-1324.

4.2. Multimodale Therapie des Pleuramesothelioms

Krug LM, Pass HI, Rusch VW et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. *J Clin Oncol* 2009; 27(18):3007-3013.

5. Mediastinaltumore

5.1. Differentialtherapie von Thymomen

D'Angello RM, Trodella L, Ramella S et al. Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. *Int J Radiation Oncology Biol Phys* 2008; 71(2):420-427.

Dango S, Passlick B, Thiemann U et al. The role of a pseudocapsula in thymic epithelial tumors: outcome and correlation with established prognostic parameters. Results of a 20-year single center retrospective analysis. *J Cardiothorac Surg* 2009; 4:33.

6 Lungenmetastasen

6.1. Radiofrequenzablation (RFA) bei Lungenmetastasen

Pennathur A, Abbas G, Qureshi I et al. Radiofrequency ablation for the treatment of pulmonary metastases. *Ann Thorac Surg* 2009; 87:1030-1039.

Schneider T, Warth A, Herpel E et al. Intraoperative radiofrequency ablation of lung metastases and histologic evaluation. *Ann Thorac Surg* 2009; 87:379-384.

7. Pleuraempyem

7.1. Initiales Behandlungsregime entscheidend für den Behandlungserfolg

Wozniak CJ, Paull DE, Moezzi JE et al. Choice of first intervention related to outcomes in the management of empyema. *Ann Thorac Surg* 2009; 87:1525-1531.

7.2. Bedeutung der Thorakoskopie beim kindlichen Empyem

Chen JS, Huan KC, Chen YC et al. Pediatric empyema: outcome analysis of thoracoscopic management. *J Thorac Cardiovasc Surg* 2009; 137(5):1195-1199.

8. Pneumothorax / Emphysem

8.1. Pneumothoraxrisiko bei Flugreisen bei Patienten mit Lymphangioliomyomatose, Lungenfibrose und Sarkoidose

Taveira-DaSilva AM, Burstein D, Hathaway OM et al. Pneumothorax after air travel in lymphangioliomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis. *Chest* 2009; 136(3):665-670.

8.2. Lungenvolumenreduktion bei homogenem Emphysem

Weder W, Tutic M, Lardinois D et al. persistent benefit from lung volume reduction surgery in patients with homogenous emphysema. *Ann Thorac Surg* 2009; 87:229-237.

9. Lungentransplantation

9.1. Langzeitergebnisse der Lungen- bzw. Herz-Lungen-Transplantation bei idiopathischer pulmonaler Hypertonie

Toyoda Y, Thacker J, Santos R et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. *Ann Thorac Surg* 2008; 86:1116-22.

10. Zwerchfell

10.1. Bedeutung der ipsilateralen Zwerchfellbeweglichkeit für die Lungenfunktion bei pneumonektomierten Patienten

Ugalde P, Miro S, Provencher S et al. Ipsilateral diaphragmatic motion and lung function in long-term pneumonectomy patients. *Ann Thorac Surg* 2008; 86:1745-1752.